SAR445419

DRUG2 trials

Sponsors

Sanofi

Conditions

Acute Myeloid LeukaemiaAllogenic Stem Cell Transplantation

Phase 1

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

TerminatedNCT05712278

SanofiAcute Myeloid Leukaemia

Start: 2023-06-16End: 2024-03-12Updated: 2026-06-05

Phase 2

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

WithdrawnNCT05726682

SanofiAllogenic Stem Cell Transplantation

Start: 2024-10-08End: 2027-10-11Updated: 2024-03-05

Related Papers

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.

2026-04-11

The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments.

2024-07-243 citations

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood2023-11-021 citations

A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

Blood2023-11-02